

# ANCO FAX News

Association of Northern California Oncologists  
Post Office Box 151109, San Rafael, California 94915-1109  
Voice: (415) 472-3960 • FAX: (415) 472-3961  
[execdir@anco-online.org](mailto:execdir@anco-online.org) • [www.anco-online.org](http://www.anco-online.org)

Vol. 15, No. 17

September 23<sup>rd</sup>, 2016

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at [www.anco-online.org/pubs.html](http://www.anco-online.org/pubs.html).

#### In this issue:

- National organizations comment on proposed CY2017 MPFS
- CMS announces relaxed MACRA timeline requirements
- *17<sup>th</sup> Multidisciplinary Management of Cancers: A Case-based Approach*

**The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members.** The next regular *ANCO FAX News* will be published on October 7<sup>th</sup>. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; [execdir@anco-online.org](mailto:execdir@anco-online.org).

**The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!**

☐ **Physician Members**

☐ **Nurses & Office Managers**

☐ **Office Staff**

☐ **Colleagues & Representatives**

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

## ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

### **ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues**

ASCO, ACCC, and ASH have submitted comments on the proposed Medicare *Physician Fee Schedule* for CY2017—read ASCO's comments at [www.asco.org/sites/new-www.asco.org/files/content-files/2017-MPFS-Comments.pdf](http://www.asco.org/sites/new-www.asco.org/files/content-files/2017-MPFS-Comments.pdf); read ACCC's comments at [www.accc-cancer.org/advocacy/pdf/2017-proposed-PFS-comments.pdf?\\_zs=bhddd1&\\_zl=uIdJ3](http://www.accc-cancer.org/advocacy/pdf/2017-proposed-PFS-comments.pdf?_zs=bhddd1&_zl=uIdJ3); read ASH's comments at [www.hematology.org/search.aspx?q=fee+schedule](http://www.hematology.org/search.aspx?q=fee+schedule).

The 2017 ICD-10-CM and ICD-10-PCS code updates, including a complete list of code titles, are available online at [www.cms.gov/Medicare/Coding/ICD10](http://www.cms.gov/Medicare/Coding/ICD10). In addition, CMS has published *Clarifying Questions and Answers Related to the July 6, 2015, CMS/AMA Joint Announcement and Guidance Regarding ICD-10 Flexibilities* that addresses some of the issues regarding the 12-month grace period or flexible implementation date ending in October 2016 (see page 8 of the document at [www.cms.gov/Medicare/Coding/ICD10/Clarifying-Questions-and-Answers-Related-to-the-July-6-2015-CMS-AMA-Joint-Announcement.pdf](http://www.cms.gov/Medicare/Coding/ICD10/Clarifying-Questions-and-Answers-Related-to-the-July-6-2015-CMS-AMA-Joint-Announcement.pdf)). Physicians are reminded that as of October 1<sup>st</sup> ICD-10-CM codes to the correct degree of specificity will be required in their submitted claims.

CMS has published a fact sheet on advanced care planning services that provides information on beneficiary eligibility, provider and location eligibility, and diagnosis requirements. Go to [www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/AdvanceCarePlanning.pdf?et\\_cid=38360448&et\\_rid=933033903&linkid=fact+sheet+on+advanced+care+planning](http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/AdvanceCarePlanning.pdf?et_cid=38360448&et_rid=933033903&linkid=fact+sheet+on+advanced+care+planning) for more information.

ASCO has joined a diverse group of

approximately 90 stakeholder organizations calling on CMS to rescind reimbursement cuts for certain lung cancer screening codes in the proposed CY2017 *Hospital Outpatient Prospective Payment System* (HOPPS) by retaining current reimbursement rates as established in the CY2016 HOPPS final rule. The proposed rule would lower reimbursement to hospital outpatient departments for both the shared decision making sessions between providers and patients for low-dose CT (LDCT) lung cancer screening and the actual screenings themselves by 64 and 44 percent, respectively. Such cuts would likely serve as a disincentive for hospital outpatient departments to offer this life-saving screening.

The *Community Oncology Alliance* (COA) recently testified before the *House Committee on the Budget* regarding CMS's proposed Medicare Part B experiment. After the hearing, several *Representatives* began circulating a letter to CMS that looks to rein in overreach by CMMI asking CMMI to stop experimenting with Americans' health and cease all mandatory demos. Additionally, they ask CMMI to ensure that future models comply with current law, including appropriate limitations on the size and scope of the models and not expanding models without *Congressional* approval. Read the letter at [www.communityoncology.org/2016/09/20/september-20-reps-tom-price-paulsen-boustany-circulate-letter-to-cms/](http://www.communityoncology.org/2016/09/20/september-20-reps-tom-price-paulsen-boustany-circulate-letter-to-cms/) and ask your *Representative* sign it today.

CMS has announced that it will allow physicians to choose the level and pace at which they comply with the new MACRA Medicare payment reforms. Participating at any level in 2017 will ensure that you will not be hit with payment penalties in 2019. Under the MIPS fee-for-service program, the most lenient participation option would allow physicians to simply "test" the program to ensure that their systems are working and that they are prepared for broader implementation in 2018 and beyond. While physicians who choose this option will not receive bonus payments, they will avoid a negative penalty. Under the second option, physicians can opt to submit data for less than the full reporting year. While CMS has not yet specified the timeline, it is believed that the 2017 reporting period could be only 90-180 days. Physicians who choose this option would not only avoid a negative payment adjustment, but could receive a small bonus. The third option is to participate for the full calendar year. Under this option your practice could qualify for a modest

positive payment adjustment. Finally, the fourth option is to participate in an advanced alternative payment model (APM) in 2017. If you receive enough of your Medicare payments or see enough of your Medicare patients through an APM in 2017, then you would qualify for a 5% incentive payment in 2019. Read CMS's announcement at [blog.cms.gov/2016/09/08/qualitypaymentprogram-pickyourpace/](http://blog.cms.gov/2016/09/08/qualitypaymentprogram-pickyourpace/) and ASH's summary at [www.hematology.org/Advocacy/Policy-News/2016/6688.aspx](http://www.hematology.org/Advocacy/Policy-News/2016/6688.aspx).

**The 2015 Physician Quality Reporting System (PQRS) feedback reports will be available in September 2016 for individual eligible professionals and PQRS group practices.** The PQRS feedback reports will provide the final determination on whether or not participants met the PQRS criteria for avoiding the 2017 PQRS negative payment adjustment. Additional information about the 2015 PQRS feedback reports and how to request an informal review will be available on the PQRS website ([www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/2015\\_Physician\\_Quality\\_Reporting\\_System.html](http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/2015_Physician_Quality_Reporting_System.html)) and through the QualityNet Help Desk at (866) 288-8912 or [qnetsupport@hcqis.org](mailto:qnetsupport@hcqis.org). **The 2015 annual Quality and Resource Use Reports (QRURs) will also be available in September 2016 for groups with 2 or more eligible professionals and solo practitioners.** Groups and solo practitioners are identified in the QRURs by their *Taxpayer Identification Number*. Additional information about the 2015 annual QRURs and how to request an informal review is available at [www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/2015-QRUR.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/2015-QRUR.html) or through the QRUR Help Desk at [pvhelpdesk@cms.hhs.gov](mailto:pvhelpdesk@cms.hhs.gov) or (888) 734-6433 (option 3).

### **CMA, MOASC, and State Legislative & Regulatory Issues**

Forthcoming CMA webinars include:

- CHPI Physician Quality Rating Program: Navigating the Review and Corrections Process (October 5)

Contact CMA's member help center at (800) 786-4262 or [memberservice@cmanet.org](mailto:memberservice@cmanet.org) for more information. Register online at [www.cmanet.org/events](http://www.cmanet.org/events).

**CMA Practice Resources (CPR)** is a monthly e-mail bulletin from CMA's *Center for Economic*

*Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit [www.cmanet.org/cpr](http://www.cmanet.org/cpr) to subscribe. The September 2016 edition includes:

- United Healthcare fails to provide proper notification on rollout of clinical data submission protocol
- New CMA resource clarifies prohibitions on balance billing Medi-Medi patients
- Free CME: CMA hosts webinar on pain management and safe prescribing
- Know Your Rights: Making the most out of your appeals
- The Coding Corner: ICD-10 raises the diagnosis coding stakes on October 1

### **Noridian/JEMAC, DHCS/MediCal, & Private Payers**

**Noridian Administrative Services is the Jurisdiction E (JE) Medicare Administrative Contractor (MAC).** Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at [med.noridianmedicare.com/web/jeb](http://med.noridianmedicare.com/web/jeb). Recent updates include:

- MLN Connects Provider eNews *Announcements*—2015 PQRS Feedback Reports and 2015 QRURs: Are You Ready?; Plans for Quality Payment Program in 2017: Pick Your Pace; EHR Incentive Programs: Materials from August Webinars Available; ICD-10 Coordination and Maintenance Committee Meeting: Materials Available; Track ICD-10 Progress and Manage Your Revenue Cycle *Claims, Pricers, and Codes*—October 2016 Average Sales Price Files Now Available *Events*—SNF Value-Based Purchasing Program Call-September 28; 2015 Annual QRURs Webcast-September 29 *Publications*—Advance Care Planning Fact Sheet-New; Overview of the SNF Value-Based Purchasing Program MLN Matters Article-New; Fee-For-Service Data Collection System: Clinical

Laboratory Fee Schedule Data Reporting Template MLN Matters Article-New; Clinical Laboratory Fee Schedule Fact Sheet-Revised; ICD-10-CM/PCS Myths and Facts Fact Sheet-Revised; ICD-10-CM Classification Enhancements Fact Sheet-Revised; ICD-10-CM/PCS The Next Generation of Coding Fact Sheet-Revised; General Equivalence Mappings Frequently Asked Questions Booklet-Revised

- Coding Revisions to NCDs CR9751
- Enrollment on Demand Application Tutorials Recently Added
- HPTC-October 2016 Code Set Update CR9659
- HCPCS Codes for SNF CB-2017 Annual Update CR9735
- Claims Status Category and Claim Status Codes Update CR9680
- Ordering and Referring Providers
- Lunch and Learn Webinar Series for MCD
- CERT A/B MAC Education Resources-Now Available
- MolDX: Blueprint; 4q25-AF Risk Genotype; BLM Gene Analysis; CHD7 Gene Analysis; ApoE Genotype; ATP7B Gene Tests; BCKDHB Gene Test; Aspartoacyclase 2 Deficiency (ASPA) Testing; 9p21 Genotype; CFTR Gene Analysis; ENG and ACVRL1-Billing and Coding Guidelines
- Diagnostic and Therapeutic Colonoscopy Draft LCD Published for Review and Comments
- MolDX: Molecular Diagnostic Tests (MDT) LCD-R2
- Chest X-Ray Draft LCD Published for Review and Comments
- Revenue Code Clarification for HCPCS Code Q4081
- Fee-For-Service Data Collection System: Clinical Laboratory Fee Schedule Data Reporting Template-Revised SE1620
- Overview of the Skilled Nursing Facility Value-Based Purchasing Program
- MolDX-CDD Percepta Bronchial Genomic Classifier Draft LCD Published for Review and Comments

- MolDX: APC and MUTYH Gene Testing Draft LCD Published for Review and Comments
- MLN Connects Provider eNews-September 15, 2016

*Noridian/JEMAC's* Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at [www.edissweb.com/cgp/news/index.html](http://www.edissweb.com/cgp/news/index.html).

#### **Forthcoming *Noridian/JEMAC* meetings/workshops include:**

- Advance Beneficiary Notice of Noncoverage (ABN; September 27)
- Appeals I (September 27)
- Appeals II (September 28)
- Appeals III (September 29)
- Getting Paid and Keeping It-In-Person Seminar (Union City, October 25)
- Evaluation and Management Modifiers (October 26)
- Ordered, Referred and Prescribed Services (November 15)

Visit [med.noridianmedicare.com/web/jeb/education/training-events](http://med.noridianmedicare.com/web/jeb/education/training-events) for more information and to register.

***Noridian/JEMAC* will soon be deactivating billing privileges for physicians who received revalidation notices from *Noridian* but have not submitted completed applications to CMS.**

*Noridian/JEMAC* reports that only 19% of physicians have responded to the most recent revalidation process. To prevent deactivation, CMA recommends that practices look up their revalidation dates through the CMS look-up tool. If it shows that your practice missed the deadline, then you should submit and sign your application online immediately. Visit [med.noridianmedicare.com/web/jeb/article-detail/-/view/10546/provider-enrollment-revalidation-cycle-2](http://med.noridianmedicare.com/web/jeb/article-detail/-/view/10546/provider-enrollment-revalidation-cycle-2) for more information.

**DHCS/MediCal is surveying physicians for feedback on the effectiveness of DHCS/MediCal's fee-for-service provider relations activities, including the telephone service center, cash control unit, regional reps, publications, and provider seminars/trainings.** Learn more about the survey and participate at [www.cmanet.org/news/detail/?article=practices-encouraged-to-take-dhcs-medi-cal](http://www.cmanet.org/news/detail/?article=practices-encouraged-to-take-dhcs-medi-cal).



**Subscribe today to receive the DHCS/Medi-Cal Subscription Service (MCSS) via e-mail.** The MCSS is a free service that can help keep you up-to-date on the latest DHCS/MediCal news. Go to the MCSS Subscriber Form ([files.medi-cal.ca.gov/pubsdoco/mcss/mcss.asp](http://files.medi-cal.ca.gov/pubsdoco/mcss/mcss.asp)) to subscribe.

**A list of DHCS/MediCal webinars** is at <https://learn.medi-cal.ca.gov>.

## EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

### **ANCO's 2016 Hematological Malignancies Updates**

ANCO is organizing a series of *Hematological Malignancies Updates* in 2016. The second *Update* took place on September 17<sup>th</sup> at the *Hyatt Regency Sacramento* with Bruno Medeiros, M.D., *Stanford University*, Aaron Rosenberg, M.D., *University of California, Davis*, and Rajeev Krishnan, M.D., *University of California, Davis*. The latest research on novel treatment modalities for acute and chronic leukemias, and myeloma, along with case studies for these diagnoses were presented. Download the presentations at [www.anco-online.org/education.html](http://www.anco-online.org/education.html).

### **SAVE THE DATE 17<sup>th</sup> Multidisciplinary Management of Cancers: A Case-based Approach**

The 17<sup>th</sup> *Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 17-19<sup>th</sup>, 2017. The meeting is sponsored by the *University of California, San Francisco, Office of Continuing Medical Education* and the *Association of Northern California Oncologists* and presented in collaboration by the *Stanford Cancer Institute*, *UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. Go to [www.multicancers.org](http://www.multicancers.org) to receive registration, housing, and additional information about this meeting as it becomes available.

### **Additional Education Meetings**

Other meetings of possible interest to ANCO

September 30<sup>th</sup>

*Advances in the Treatment of Renal Cell Cancer*  
CancerCare Connect Education Workshop

([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

September 30<sup>th</sup>

*ICLIO National Conference: Immuno-Oncology—There's More to Discover*  
ACCC's Institute for Clinical Immuno-Oncology  
Philadelphia  
([acc-iclio.org/events/iclio-2nd-national-conference/](http://acc-iclio.org/events/iclio-2nd-national-conference/))

October 5<sup>th</sup>

*Update on Triple Negative Breast Cancer (Part I of Living with Triple Negative Breast Cancer)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 6<sup>th</sup>

*Update on Mantle Cell Lymphoma*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 19<sup>th</sup>-21<sup>st</sup>

*ACCC 33<sup>rd</sup> National Oncology Conference: The How-To Conference for the Cancer Care Team*  
Association of Community Cancer Centers  
St. Louis  
([www.accc-cancer.org/meetings/NOC2016.asp](http://www.accc-cancer.org/meetings/NOC2016.asp))

October 26<sup>th</sup>

*Coping with the Stresses of Caregiving When Your Loved One Has Triple Negative Breast Cancer (Part II of Living with Triple Negative Breast Cancer)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 27<sup>th</sup>

*Living with Metastatic Breast Cancer*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 30<sup>th</sup>-November 2<sup>nd</sup>

*2016 Annual Conference*  
Medical Group Management Association  
San Francisco  
([www.mgma.com/annual-conference/why-attend](http://www.mgma.com/annual-conference/why-attend))

November 1<sup>st</sup>

*Advances in the Treatment of Lung Cancer (Part I of Living with Lung Cancer)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

November 2<sup>nd</sup>

*Treatment Update on Pancreatic Cancer (Part I of Living with Pancreatic Cancer)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

November 3<sup>rd</sup>

*Update on Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

November 7-9<sup>th</sup>

*Novel Cancer Therapeutics Summit 2016*  
Global Technology Community

November 15<sup>th</sup>

*For Caregivers: Practical Tips for Coping with Your Loved One's Lung Cancer (Part II of Living with Lung Cancer)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

November 16<sup>th</sup>

*For Caregivers: Coping with Your Loved One's Pancreatic Cancer (Part II of Living with Pancreatic Cancer)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

November 17<sup>th</sup>

*Advances in Immunotherapy in the Treatment of Lymphoma*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

December 3<sup>rd</sup>-6<sup>th</sup>

*58<sup>th</sup> ASH Annual Meeting & Exposition*  
American Society of Hematology  
San Diego  
([www.hematology.org/Annual-Meeting/](http://www.hematology.org/Annual-Meeting/))

December 12<sup>th</sup>

*Update on Lymphoma from the 2016 American Society of Hematology (ASH) Annual Meeting*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

January 19<sup>th</sup>-21<sup>st</sup>

*2017 Gastrointestinal Cancers Symposium: Multidisciplinary Precision Care—Progress and Innovation*  
American Society Clinical Oncology  
San Francisco  
(<http://gicasymp.org>)

January 27-28<sup>th</sup>

*Cancer Survivorship Symposium: Advancing Care and Research—A Primary Care and Oncology Collaboration*  
American Society Clinical Oncology  
San Diego  
(<http://survivorsym.org>)

Please contact the ANCO office for more information about these meetings.

## ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

### Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors teleconference is scheduled for October 18<sup>th</sup>**. Please call José Luis González, ANCO *Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

### Individual Member News

A current *Directory of Members* is available online at [www.anco-online.org/pubs.html](http://www.anco-online.org/pubs.html) as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at [execdir@anco-online.org](mailto:execdir@anco-online.org) with any corrections, additions, and/or deletions.

### Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Pacific Cancer Care*, *Palo Alto Medical Foundation*, and *Valley Medical Oncology Consultants* for their multi site group memberships.

### Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the

following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

**UC Davis's 17<sup>th</sup> Annual Advances in Oncology 2016 takes place on September 30<sup>th</sup>-October 1<sup>st</sup> in Sacramento.** The Lois O'Grady Lectureship, entitled *Update on ALL Research and Therapy* with Hagop Kantarjian, M.D., *University of Texas MD Anderson Cancer Center*, takes place on September 30<sup>th</sup>. For more information and to register, go to [meccinc.com/conferences/oncology](http://meccinc.com/conferences/oncology)/or e-mail [tvalls@meccinc.com](mailto:tvalls@meccinc.com).

**Stanford's Hematology Review of the 58<sup>th</sup> Annual ASH Meeting takes place on February 4<sup>th</sup> in Half Moon Bay.** For more information and to register, go to [cme.stanford.edu/hematology](http://cme.stanford.edu/hematology).

### Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Alexion Pharmaceuticals • AMGEN  
ARIAD Pharmaceuticals • Astellas Oncology  
AstraZeneca • Bayer Healthcare Pharmaceuticals  
Boehringer Ingelheim Pharmaceuticals  
Bristol-Myers Squibb Oncology  
Cardinal Health Specialty Solutions  
Celgene • Clovis Oncology • Daiichi Sankyo  
Dendreon • Eisai • Exelixis  
Foundation Medicine  
Genoptix Medical Laboratory  
GenPath Oncology • Genentech BioOncology  
Genomic Health • Gilead Sciences  
Guardant Health • Helsinn Oncology  
Heron Therapeutics • Incyte  
Infinity Pharmaceuticals  
Ipsen Biopharmaceuticals  
Janssen Oncology • Jazz Pharmaceuticals  
Lilly Oncology • Merrimack Pharmaceuticals  
Medivation • Merck  
nanoString • Novartis Oncology  
Oncology Supply/ION • Pfizer Oncology  
Pharmacyclics • Prometheus Laboratories, Inc.  
Sandoz Biopharmaceuticals • Sanofi Genzyme  
Seattle Genetics • Taiho Oncology  
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *AbbVie, ARIAD Pharmaceuticals, Clovis Oncology, Exelixis, GenPath Oncology, Guardant Health, Heron Therapeutics, Infinity Pharmaceuticals, Ipsen Pharmaceuticals, Jazz Pharmaceuticals, Merrimack Pharmaceuticals, Prometheus Laboratories, Inc., Sandoz Biopharmaceuticals, Taiho Oncology, and Tesaro* as new Corporate Members for 2016. *Biodesix, Onyx Pharmaceuticals, and Sargas Pharmaceutical Adherence & Compliance (SPAC) International* did not renew their memberships for 2016. Please visit [www.anco-online.org/assistance.html](http://www.anco-online.org/assistance.html) for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

*AbbVie* will host a clinical discussion entitled *Venclexta for Treatment of Previously Treated CLL with 17p Deletion* with Steven Rosen, MD, *City of Hope Comprehensive Cancer Center*, on September 29<sup>th</sup> in Palo Alto. Please RSVP by September 26<sup>th</sup> to Greg Bennett at (760) 625-2449 or go to [abbvie.meintl.com/OHD08-OB01-16](http://abbvie.meintl.com/OHD08-OB01-16).

*AMGEN* informs ANCO that the *United States Food and Drug Administration* has approved Blincyto for use in pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

*Bristol-Myers Squibb Oncology* informs ANCO that the *United States Food and Drug Administration* has modified the dosage regimen for Opdivo for the currently approved indications for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer. The currently approved recommended dosage regimens were modified to 240mg IV every two weeks.

*Exelixis* informs ANCO that Cabometyx is now approved for patients who have received prior therapy for advanced renal cell carcinoma (RCC). It has an NCCN Category 1 recommendation for patients with advanced clear cell histology RCC after prior anti-angiogenic therapy.

*Genentech BioOncology* is hosting a series of three webcasts across two days (September 28-29) entitled *Introducing Tecentriq: The First and Only FDA-Approved Anti-PDL1 Immunotherapy for Previously Treated Locally Advanced Metastatic Urothelial Carcinoma*. Go to



[www.medforcereg.net/SGEN6080](http://www.medforcereg.net/SGEN6080) for more information and to register.

**Novartis Oncology** informs ANCO that the *United States Food and Drug Administration* has approved an additional indication for Arzerra. The additional indication is its use in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).

**Pharmacyclics** will host an exhibitor theater to discuss *Imbruvica* in CLL/SLL with Keven R. Kelly, MD, *University of Southern California*, on October 29<sup>th</sup> in Anaheim. Please RSVP at [bit.ly/registerCSHP](http://bit.ly/registerCSHP).

### **Publications, Resources, Services, & Surveys**

ANCO and MOASC have partnered with **SullivanLuallin Group** to offer your practice the opportunity to participate in an **Oncology-based Patient Satisfaction Survey**. The Survey is designed to assess your organization's performance in key areas associated with the ACO and PQRS CAPHS Surveys. **SullivanLuallin Group's eSurvey: Online Patient Satisfaction Survey** platform allows you to efficiently and cost-effectively capture how your patients feel about your systems, services, and performance. Download more information and an enrollment form at [www.anco-online.org/PtSurvey2016.pdf](http://www.anco-online.org/PtSurvey2016.pdf).

**ANCO and MOASC are jointly conducting a 2016 staff salary survey.** The survey was e-mail/FAXed to all members in mid-May and is available online at [www.anco-online.org/salsrvy.html](http://www.anco-online.org/salsrvy.html). A \$50 Visa gift card for respondents is included in this year's survey. Return your completed survey no later than September 30<sup>th</sup>; results will be analyzed and reported in 4Q2016.

The September 2016 issue of **ASCO's Journal of Oncology Practice (JOP)** is available online and features articles entitled *What Adult Cancer Care Can Learn from Pediatrics*, *Creating Virtual Integration and Improved Oncology Care Quality Through a Co-Management Services Agreement*, and *Leveraging Emerging Technologies and the "Internet of Things" to Improve the Quality of Cancer Care*. Visit [jop.ascopubs.org](http://jop.ascopubs.org) for more information.

**Free PQRS reporting is now available through ASCO's Quality Oncology Practice Initiative (QOPI).** All users will be able to use the QOPI

system to fulfill the Oncology Measures Group set of seven measures for PQRS reporting. Learn more at [www.asco.org/advocacy-policy/asco-in-action/free-pqrs-reporting-now-available-through-qopi](http://www.asco.org/advocacy-policy/asco-in-action/free-pqrs-reporting-now-available-through-qopi). QOPI is designed to promote excellence in cancer care by helping oncologists create a culture of self-examination and improvement. ASCO offers the **QOPI Certification Program** to recognize QOPI participants who achieve rigorous standards for cancer care. The **QOPI Certification** designation can be used by certified practices to demonstrate an advanced commitment to quality and are eligible to receive a discount of up to 10% on medical malpractice rates from *The Doctors Company*, the nation's largest physician-owned medical malpractice insurer. Go to [www.instituteforquality.org/qopi-qcp](http://www.instituteforquality.org/qopi-qcp) for more information.

**ACCC has launched a free multimedia, online learning portal** at [www.accc-cancer.org/elearning](http://www.accc-cancer.org/elearning) that provides two-way, engaging education on operational, administrative, and clinical topics.

**ACCC's online Oncology Drug Database provides quick access to information on oncology drug coding, billing, and reimbursement** at [www.accc-cancer.org/drugdatabase/](http://www.accc-cancer.org/drugdatabase/).

**ACCC's enhanced set of Financial Advocacy Network resources** are at [www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp](http://www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp). This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

**NCCN has published and/or updated their Clinical Practice Guidelines in Oncology and/or Drugs & Biologics Compendium** for cervical cancer (V1.2016); genetic/familial high-risk assessment: breast and ovarian (V1.2017); head and neck cancers: lip and oral cavity (V1.2016); Hodgkin lymphoma, multiple myeloma, and non-Hodgkin's lymphomas (translations); older adult oncology (V2.2016); ovarian cancer (V1.2016); prostate cancer (V2.2016); small cell lung cancer (V2.2017); smoking cessation (V1.2016).